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Abstract 
Purpose: To prepare and characterize tablets loaded with self-nanoemulsifying drug delivery system 
(SNEDDS) containing docetaxel (DTL).  
Method: SNEDDS of docetaxel were prepared using various oils, surfactants, co-surfactant and 
solvents to improve the dissolution rate and bioavailability of the poorly water-soluble chemotherapeutic 
agent. The SNEDDS components were preliminarily screened for the solubility of the drug in various 
vehicles, miscibility of excipients, rate of emulsification and ternary phase diagrams. The tablets were 
prepared by direct compression process with a porous carrier, magnesium alumino-metasilicate, and 
subsequently loaded with SNEDDS by a simple absorption method. The tablets were then characterized 
for physical parameters, including tablet hardness, weight variation, disintegration, drug content and in-
vitro drug release.  
Results: Cremophor-EL, polysorbate-80 and dehydrated alcohol mixture in the ratio 85:10:5 yielded 
docetaxel SNEDDS with droplet size of 12.16 nm and polydispersity (PDI) of 0.039. Tablets with high 
porosity suitable for loading with SNEDDS and containg the super-disintegrants, crosscarmellose 
sodium and sodium starch glycolate, in a concentration of 3, 4 and 5 %, achieved complete dissolution 
of docetaxel from the tablets. In vitro release of docetaxel from SNEDDS and the tablets was similar (p 
< 0.05). 
Conclusion: SNEDDS of docetaxel is a promising approach to achieving a solid dosage form of the 
liquid-loaded drug delivery systems for enhancing the solubility and dissolution rate of the drug, and 
hence also its bioavailability. 
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High levels of insolubility in the formulation of 
anticancer injections pose serious problems and 
challenges to formulation scientists and 
physicians in terms of emulsifying and 
suspending injectable formulations. Currently, 
docetaxel injection is available as SNEDDS 
formulation with polysorbate-80, which 
accommodates effective therapeutic amount in 
smaller amount of surfactant mix. Hence, 
formulation development in these areas using 
SNEDDS is feasible to have pharmaceutical 
equivalent dosage form.  
Rao et al 




However, new technologies has been developed 
for sealing of soft and hard gelatin capsules [1,2]. 
Some formulators have focused on solid 
formulation of lipid systems and in particular 
formulation of liquids and semi-solid self-
emulsifying drug delivery systems (SEDDS) [3]. 
Lipid-based formulation systems have become 
increasingly important in the formulation of 
lipophilic drug substances as they can facilitate 
the dispersion of a drug in the gastrointestinal 
tract resulting in enhanced oral bioavailability [4]. 
Self-nanoemulsifying mixture is an advanced 
form of nanoemulsion drug delivery systems, 
because water is not used and so the drug 
leaching from the nanosized oily droplets to the 
aqueous medium of the formulation during 
storage is minimized [6].  
 
Generally, self-emulsifying mixtures are broadly 
classified according to their sizes such as: 
SMEDDS with droplets of emulsion size is more 
than 600 nm. SMEDDS with droplets of micron 
sizes, i.e., lies between 100 - 150 nm and 
SNEDDS with droplets of nanosized between 10-
100 nm [5]. Transfer of liquid lipid systems into a 
solid oral dosage form has been attempted by 
several methods such as capsule filling and 
spray drying [6], adsorption onto solid carriers [7-
9] and melt granulation as well as other 
techniques [10]. However, a large amount of 
carrier is required to solidify the liquid, which 
subsequently results in the production of a large 
dosage volume [11].  
 
The objective of this study was to develop and 
evaluate self-nanoemulsifying formulations 
containing poorly water soluble anti-mitotic 






Docetaxel (DTL) was obtained as a gift from 
Aptuit Laurus Laboratories, India. 
Polyethoxylated castor oil (CremophornEL), 
polysorbate-80, PEG (polyethylene glycol) 400, 
propylene glycol, polyethylene glycol-15-hydroxy 
stearate (Solutol®HS-15), propylene glycol 
monocaprylate (type II) NF (Capryol®90), 
glyceryl caprylate/caprate (Capmul®MCM), 
Capryol-90, Capmul-MCM, lauroglycol, capryl 
ocaproyl polyoxyl-8 glycerides NF (Labrasol®), 
propylene glycol dicaprylate/dicaprate NF 
(Labrafac®), highly purified diethylene glycol 
monoethyl ether EP/NF (Transcutol®P), 
dehydrated alcohol. Magnesium aluminum 
metatrisilicate and other chemicals used in the 





The solubility of docetaxel in various oils, 
surfactants, cosurfactants/solvents was 
determined. An excess amount of docetaxel was 
added into each vial containing 10 mL of 
selected vehicle. Then, the mixture was heated 
to 37 oC on water bath to facilitate the 
solubilization. Mixing of the systems was 
performed using a cyclo-mixer (CM 101, Remi, 
India) for 10 min in order to facilitate proper 
mixing of drug with the vehicle. The dispersions 
thus formed were shaken for 48 h in a 
mechanical shaker (Remi, India). After reaching 
equilibrium, the dispersions were centrifuged at 
2500 rpm for 20 min to remove undissolved 
docetaxel, followed by filtration through a 0.45 
μm millipore membrane filter paper. The 
concentration of docetaxel was quantified by high 
performance liquid chromatography (HPLC).  
 
Construction of ternary phase diagrams 
 
The ternary phase diagrams of oil, surfactant, co-
surfactant/solvents and water were developed 
using surfactant titration method. The dispersions 
of oil and water at certain weight ratios were 
titrated with surfactant/co-surfactant mix in a drop 
wise manner. Until visual observation of phase 
clarity and flowability was obtained. After the 
identification of self-nanoemulsion region in the 
phase diagrams, the SNEDDS formulations were 
selected at the desired component ratios [13,14].  
 
Preparation of DTL-SNEDDS 
 
The DTL-SNEDDS were prepared by using 
surfactants, co-surfactant, oil/ solvent mix. The 
level of docetaxel was kept constant (i.e. 20 mg). 
The concentration of surfactant and other 
components were varied in different formulations 
until freely solubilized drug with stable SNEDDS 
were produced. The docetaxel (20 mg) was 
added into the mixture and mixed using magnetic 
stirrer at ambient temperature until complete 
dissolution of docetaxel. Prepared SNEDDS 
were stored at room temperature and evaluated 
for their droplet size and polydispersity, stability 
and spectral analysis.  
 
Evaluation of SNEDDS 
 
Droplet size and polydispersity (PDI) 
 
Docetaxel SNEDDS was diluted with distilled 
water (a portion diluted 1 in 25 and if clear, the 
Rao et al 
Trop J Pharm Res, April 2015; 14(4):   
 
569 
second portion was diluted 1 in 100). The two 
portions were gently mixed and sonicated for 30 
s and allowed to settle. Clear solutions were 
used to measure droplet size/distribution and 
polydispersity was determined at 25 °C by 
photon correlation spectroscopy (PCS) using a 
Malvern Nanosizer/Zetasizer® (Malvern 
Instruments, USA). The analysis was performed 
to determine mean values/ Z-Average of particle 
size distribution. Turbid and opaque dispersions 
were evaluated visually. The droplet size and 




Freeze thawing was employed to evaluate the 
stability of drug loaded SNEEDS. Formulations 
were subjected to 3 freeze-thaw cycles, which 
included freezing at −20 °C for 48 h followed by 
thawing to ambient room temperature (37 °C) for 
48 h. Nanoemulsions were observed for physical 
stability conditions such as phase separation or 
drug precipitation. 
 
Preparation of porous tablets 
 
The porous tablets were prepared by direct 
compression process. Porous adsorbent 
magnesium aluminum metatrisilicate (MAMS) 
granules was mixed with super-disintegrants and 
lubricated. All the ingredients were mixed in a 
cylindrical blender and directly compressed into 
tablets using 16 station rotary compression tablet 
press (Mini Press manufactured by ELITE 
Scientific Pvt Ltd). Tablets average weight of 860 
mg compressed using a round 12.5 mm flat-
faced punches were produced. The compositions 
of various porous tablets are given in Table 1. 
The prepared tablets were subjected to 
evaluation of physical parameters such as 
thickness, hardness and disintegration test 




Tablets were placed in slightly excess of 
docetaxel-SNEDDS and allowed to absorb the 
liquid over a period of 24 h. Tablets surface 
exposed to SNEDD was rotated after 12 h. After 
the exposure, tablets surface was drained by 
using absorbent pad and the weight of tablets 
were recorded. The loaded tablets were dried at 
ambient conditions over a period of 3 days.  
Furthermore, the tablets were characterized for 
percentage loading by weight and for 
disintegration.  To make maximum feasible time 
for loading, tablets were compressed as porous 
plugs with a thickness of 6.5 ± 0.3 mm. 
 
In vitro dissolution studies 
 
Dissolution rate studies of DTL-SNEDDS were 
performed using USP dissolution testing 
apparatus (type II) with rotating paddles at 100 
rpm using 900 ml of distilled water as dissolution 
medium. The temperature was maintained at 37 
± 0.5 °C throughout the experiment. Aliquots (10 
ml) were withdrawn at various time intervals and 
same volume of dissolution medium was 
replaced for maintaining the constant volume of 
dissolution medium. Samples were filtered 
through 0.45 µ filter and analyzed by HPLC 
[15,16].  
 
Assay of DTL in SNEDDS 
 
An HPLC system (Waters HPLC 2 2695 Series) 
consisting of pump, Auto sampler, UV-Vis 
detector, Thermostat column compartment 
connected with Waters (alliance) Empower 
software equipped with a 230 nm UV-detector 
and YMC ODS C18, 250 x 4.6 mm, 5 µ, was 
maintained at constant temperature of 30 °C. A 
sample volume of 20 μL DTL solution was 
injected. The gradient system consisted of 2 
mobile phases with the compositions of mixed 
Phosphate buffer which consist of 1.6 g of 
potassium dihydrogen phosphate and 0.3 g of 
Dipotassium hydrogen phosphate in 1 L of water 
(pH 5.80): Acetonitrile in the ratio 30: 70. The 
flow rate was kept constant at 1.0 mL per min. 
 
 
Table 1: Composition of porous tablets 
 
Content (mg) 
Ingredient A1 A2 A3 A4 A5 A6 B1 B2 
MAMS 830.25 821.75 813.25 830.25 821.75 813.25 791.60 791.60 
Sodium starch glycolate 25.50 34.00 42.50 -- -- -- 42.50 25.50 
Crosscarmellose  sodium  -- -- -- 25.50 34.00 42.50 25.50 42.50 
Magnesium stearate 
(0.5%) 
4.25 4.25 4.25 4.25 4.25 4.25 4.25 4.25 
Total weight (mg) 860 860 860 860 860 860 860 860 
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Initially solubility studies were performed to 
identify suitable oily phase, surfactants, and 
cosurfactants for the development of SNEDDS of 
docetaxel. Because solubility of the drug is an 
important consideration when formulating a self-
emulsifying formulations for avoiding precipitation 
of the drug on dilution in the in vivo. The 
concentration of docetaxel was quantified by 
HPLC. The results of solubility studies are 
reported in Figure 1. 
 
Ternary phase diagrams 
 
Based on the results of preliminary studies, 
ternary phase diagrams of the seven systems 
were constructed with the objective to study the 
relationship between the phase behavior and the 
composition also help to determine the 
concentration range of components for the 
formation of a nano emulsion. All the 
components were converted to weight/weight 
percent (w/w %) before constructing the phase 
diagrams. The bluish area enclosed in the 
triangle represents the region of self-
emulsification (Fig 2). Within this area the 
SNEDDS form fine oil in water emulsion with only 
gentle agitation. Globule size (< 200 nm) and 
PDI (0.3 <) were the criteria for selection of the 
composition. 
 
Fig 2: Representative ternary phase diagram 
indicating the efficient self-nanoemulsion region 
containing Cremophore-EL, Polysorbate-80 and 




Figure 1: Solubility of docetaxel in various oils, surfactants, co-surfactants and solvents 
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Droplet size and polydispersity 
 
Different surfactant systems were chosen for 
SNEDDS formulation. Presence of oil phase 
components Transcutol or Capmul in surfactant 
mix yielded droplet size range below 200 nm. 
Due to fluidity and collision over oil and co-
surfactant phases upon dilution droplet growth 
was observed. Replacing oil phase with solvent 
phase made stabilization of the nano emulsion. 
Here the surfactant mix which provided the rigid 
micelle structure and the suitable solvent 
proportion decreased the friction between 
micellar layers and resulted in stable nano 
emulsion. The droplet size and polydispersity 
values of docetaxel SNEDDS formulations are 




The selected formulations were subjected to 
different thermodynamic stability by using 
heating and cooling cycle, centrifugation and 
freeze thaw cycle stress tests. Those 
formulations, which survived thermodynamic 
stress tests, were taken for dispersibility test to 
see the visual clarity after infinite dilution. There 
were no physical variations observed in set of 
SNEDDS developed with docetaxel, Cremophor, 




The granules were evaluated for their 
micromeritic properties. The results obtained 
were bulk density (0.615 g/cm3), tapped density 
(0.510 g/cm3) and angle of repose (18 °). 
 
Physical characteristics of SNEDDDS-loaded 
tablets 
 
Tablet weight was taken before loading and after 
loading as part of the characterization of loaded 
tablets. The tablet properties are given in Table 
4. 
 
In vitro dissolution of SNEDDS-loaded 
docetaxel tablets  
 
The dissolution profiles are shown in Figure 3. 
Formulations A1, A2, A3 contain sodium starch 
glycolate as superdisintegrant; formulations A4, 
A5 and A6 contain cross caremellose sodium as 
superdisintegrant, while formulations B1 and B2 
contain the combination of both disintegrants. 
 
 
Table 3: Droplet size and polydispersity (PDI) of docetaxel SNEDDS formulations 
 
Composition  Dilution Z-average 
(d.nm) 
PDI 
Polysorbate-80 +PEG-400+Transcutol-HP 1:25 85.43 0.209 
1:100 133.3 0.324 
Polysorbate-80+Soluphor-P+Capmul-MCM 1:25 29.75 0.276 
1:100 39.30 0.243 
Polysorbate-80+Glycerol+Capmul-MCM 1:25 96.89 0.434 
1:100 67.8 0.633 
Cremophor-EL+Soluphor+Capmul-MCM 1:25 10.28 0.873 
1:100 40.06 0.137 
Cremophor-EL+Glycerol+ Capmul-MCM 1:25 80.93 0.453 
1:100 78.4 0.784 
Cremophor-EL+Glycerol+Capmul-MCM 1:25 98.64 0.305 
1:100 23.67 1.000 
Cremophor-EL+Polysorbate-80+Ethanol 1:25 12.16 0.039 
1:50 12.36 0.029 
1:100 12.67 0.014 
 
Table 4: Characteristics of SNEDDS-loaded tablets 
 
Parameter A1 A2 A3 A4 A5 A6 B1 B2 
Mean weight 860 mg ± 0.4mg 
Diameter (mm) 12.5 ± 0.2 
Hardness (kg/cm2) 2.2 1.8 2.0 2.4 2.2 2.2 2.0 2.2 
Thickness (mm) 6.4±0.2 6.5±0.2 6.5±0.2 6.5±0.2 6.5±0.2 6.5±0.2 6.5±0.2 6.5±0.2 
Disintegration time 
(min) 
2-3 1-2 1-2 1-2 1-2 ≤1 ≤1 ≤1 
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Fig 3: Dissolution profile of SNEDDS-loaded 
docetaxel tablets. Note: -♦- A1, -□-A2, -▲-A3, -■- A4, -




Docetaxel SNEDDS used in preparing liquid-
loaded tablets had a particle size of 12.16 nm. 
SNEDDS dramatically enhanced the solubility of 
docetaxel. The results obtained in the study 
suggest that SNEDDS is an efficient and 
potential carrier for delivery of docetaxel by oral 
route, From the results of tablet disintegration for 
LLT it was found to influence the release of the 
loaded DTL-SMEDDS in vitro. Surfactant and co-
surfactant get preferentially adsorbed at 
interfaces, thus reducing the interfacial energy as 
well as providing a mechanical barrier to 
coalescence, and improving the thermodynamic 
stability of the nanoemulsion formulation [17]. 
  
Furthermore, co-surfactants increase interfacial 
fluidity by penetrating into the surfactant film 
creating void spaces between the surfactant 
molecules [18]. The optimum formulation of self-
nanoemulsion containing docetaxel, cremophore-
EL, polysorbate-80 and ethanol is represented by 
the ternary phase diagram in Figure 2. It was 
observed that at the dilution stage, a consistent 
droplet size was achieved when the polarity of 
docetaxel surfactant mix matches with that of 
water. Here, the association of oil phase with 
insoluble docetaxel created a high degree of 
non-polarity and micellar rearrangement, and 
thereby increased droplet size. The existence of 
emulsion after dilution is a promising SNEDD at 
micellar level as nanoemulsion with droplet size 
of 6-12 nm. Porous tablets were prepared by dry 
granulation and along with disintegrants the 
micromeritics were found to be in constant range 
and exhibited good flow properties. 
 
SNEDDs loaded tablets were shown dissolution 
rate dependant to disintegrant, in which SSG 
was proved better than CCS for a release and 
dissolution of > 95% w/w of docetaxel. Based on 
the in vitro dissolution studies Liquid loaded 
tablets of formulation A3 and B2 were found as 
optimum formulations, which were exhibited high 
dissolution rate than compared to the others. For 
these two formulations dissolution rate was 
accelerated by content of disintegrant. From 
loaded magnesium aluminometasilicate MAMS 
powder (A3), almost 97.7 % was released. The 
idea has previously been investigated for tablets 
prepared from magnesium aluminometasilicate 





Docetaxel tablet formulations incorporating 
SNEDDS for enhancement of the solubility and 
dissolution rate of a poorly soluble drug is 
feasible using the approach presented in this 
study. Furthermore, appropriate inclusion of 
surfactant and co-surfactant improves the 
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